Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

SFAS No. 123R. Amicus believes that excluding the

impact of expensing stock options better reflects the recurring

economic characteristics of its business.

(2) Other items -- Non-GAAP net loss and diluted net loss per common share

exclude other unusual or non-recurring items that are evaluated on an

individual basis. Amicus' evaluation of whether to exclude an item for

purposes of determining its non-GAAP financial measures considers both

the quantitative and qualitative aspects of the item, including, among

other things (i) its size and nature, (ii) whether or not it relates

to its ongoing business operations, and (iii) whether or not Amicus

expects it to occur as part of its normal business on a regular basis.

Items excluded for purposes of determining non-GAAP net loss and

diluted net loss per common share include deemed dividends, preferred

stock accretion, and changes in the fair value of warrant liability.

Conference Call and Webcast: First Quarter Financial Results

Amicus Therapeutics will host a conference call and webcast today, Tuesday, May 13, 2008, at 5:00 P.M. EDT to review financial results and recent developments. Interested participants and investors may access the teleconference call by dialing 877-397-0284 (U.S./Canada) or 719-325-4871 (international).

The webcast of the call can be accessed on the Investor section of Amicus' Web site at http://www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, a replay will remain available in the Investors section of Amicus' Web site for 90 days.

A telephonic replay will also be available for seven days be
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Corporation announced today the,release of two major upgrades ... a multilaser capability and the Beta release of ... field well beyond,conventional optical limitations. The Multilaser ... two additional lasers including a 405nm (violet) laser ...
... Nektar,Therapeutics (Nasdaq: NKTR ) today announced the appointment ... reports to Nektar President and,CEO Howard W. Robin, and ... management team. "With his strong understanding of healthcare ... team at Nektar," Robin said. "He brings,significant experience in ...
... 28% over the prior comparable period to A$44.4 ... comparable period to A$4.6 million -- Excluding ... period to A$2.5 million from A$2.0 million -- Reported NPAT ... comparable period including one-off items -- Ellex brand product ...
Cached Biology Technology:Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System 2Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer 2Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer 3Ellex FY2007 Year End Results 2Ellex FY2007 Year End Results 3
(Date:4/20/2014)... doctors have long known that people with Down syndrome ... (ALL) during childhood, they haven,t been able to explain ... investigators has uncovered a connection between the two conditions. ... journal Nature Genetics , the researchers track the ... in Down syndrome to the cellular havoc that occurs ...
(Date:4/18/2014)... world population predicted to reach 9 billion by ... that considers human-altered landscapes such as farmland, according ... habitat that supports it might be an increasingly ... three-quarters of the land surface is directly affected ... human-caused impacts such as climate change. But what ...
(Date:4/18/2014)... Asteroid and comet impacts can cause widespread ecological ... even global scales. But new research from Brown University ... ancient life at the time of an impact. , ... has found fragments of leaves and preserved organic compounds ... in Argentina. The material could provide a snapshot of ...
Breaking Biology News(10 mins):Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3
... Love," conducted by Syracuse University Professor Stephanie Ortigue, reveals ... same euphoric feeling as using cocaine, but also affects ... in love only takes about a fifth of a ... and an adjunct assistant professor of neurology, both in ...
... at LSU Health Sciences Center New Orleans has found that ... the hormone that regulates water retention in the body on ... for diseases like high blood pressure, congestive heart failure, and ... November 1, 2010 issue of Endocrinology . Daniel Kapusta, ...
... has created a Green Carbon Center to bring the benefits ... other energy sources together in a way that will not ... a means to recycle carbon dioxide into useful products. ... fact is humans are throwing away a potentially valuable resource ...
Cached Biology News:Falling in love 'more scientific than you think,' according to Syracuse University professor 2LSUHSC study IDs proteins regulating water retention in salt-sensitive hypertension 2Green Carbon Center takes all-inclusive view of energy 2Green Carbon Center takes all-inclusive view of energy 3
... allows the Thermo-Fast® 96 ... PCR plates to be ... PRISM® 3700 capillary sequencer. ... information on the software ...
... • Heat activated ,• ... room temperature ,• Excellent specificity allows ... and secondary structures ,• Leaves an ... chemically modified form of GeneChoice DNA Polymerase ...
... aqueous solution. Cleaves a-(1-3)- ... carbohydrates and glycoproteins. It is particularly efficient ... the pH must be neutral or above, ... Unit Definition: One unit will ...
This adapter allows the Thermo-Fast® 96 Semi-Skirted (AB-0900 and AB-0990) PCR plates to be used directly in the ABI PRISM® 3100 sequencer without the need for software changes....
Biology Products: